The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...
Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...
The need to change regulations around gene-editing treatments was endorsed in November by the head of the US Food and Drug ...
A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...
Investor's Business Daily on MSN
Beam soars nearly 30% as FDA signs off on its ambitious gene-editing plan
Beam stock launched Monday after the company reached a deal with the Food and Drug Administration for its gene-editing drug, ...
Thanks to genetic science, gene editing, and techniques like cloning, it’s now possible to move DNA through time, studying ...
Aurora Therapeutics today announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing therapies to millions of ...
As CRISPR moves from lab success to real-world medicine, 2026 will test whether these revolutionary gene-editing therapies ...
This article is the third in a series that U.S. News & World Report will publish on six major investing megatrends taking shape over the next decade. To discern which ...
A large genetic screen has revealed how stem cells transform into brain cells, exposing hundreds of genes that make this ...
In this article, we will be taking a look at the 8 gene-editing stocks to buy. Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback